"compound 25"

mutant KRASG12C allosteric covalent inhibitor

orally efficacious in XG model

from optimization of literature starting point

J. Med. Chem. Feb. 5, 2020

AstraZeneca, Cambridge, UK

KRAS(G12C) inhibitor from AZ (AstraZeneca oral in vivo mutant KRAS(G12C) allosteric covalent inhibitor)

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.